izpis_h1_title_alt

Results of dynamic contrast-enhanced ultrasound correlate with treatment outcome in canine neoplasia treated with electrochemotherapy and interleukin-12 plasmid electrotransfer
ID Brložnik, Maja (Author), ID Kranjc Brezar, Simona (Author), ID Boc, Nina (Author), ID Knific, Tanja (Author), ID Čemažar, Maja (Author), ID Milevoj, Nina (Author), ID Serša, Gregor (Author), ID Tozon, Nataša (Author), ID Pavlin, Darja (Author)

.pdfPDF - Presentation file, Download (1,95 MB)
MD5: EF84E9F0DED3CCB42B7F9F9AC11EC108
URLURL - Source URL, Visit https://www.frontiersin.org/articles/10.3389/fvets.2021.679073/full This link opens in a new window

Abstract
Electrochemotherapy (ECT) and/or gene electrotransfer of plasmid DNA encoding interleukin-12 (GET pIL-12) are effective treatments for canine cutaneous, subcutaneous, and maxillofacial tumors. Despite the clinical efficacy of the combined treatments of ECT and GET, data on parameters that might predict the outcome of the treatments are still lacking. This study aimed to investigate whether dynamic contrast-enhanced ultrasound (DCE-US) results of subcutaneous tumors differ between tumors with complete response (CR) and tumors without complete response (non-CR) in dogs treated with ECT and GET pIL-12. Eight dogs with a total of 12 tumor nodules treated with ECT and GET pIL-12 were included. DCE-US examinations were performed in all animals before and immediately after therapy as well as 8 h and 1, 3, and 7 days later. Clinical follow-up examinations were performed 7 and 14 days, 1 and 6 months, and 1 year after treatment. Numerous significant differences in DCE-US parameters were noted between tumors with CR and non-CR tumors; perfusion and perfusion heterogeneity were lower in CR tumors than in non-CR tumors. Therefore, studies with larger numbers of patients are needed to investigate whether DCE-US results can be used to predict treatment outcomes and to make effective decisions about the need for repeated therapy or different treatment combinations in individual patients.

Language:English
Keywords:dog, contrast-enhanced ultrasonography, electrochemotherapy, immunotherapy, gene electrotransfer, bleomycin, cisplatin, IL-12 plasmid
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:VF - Veterinary Faculty
MF - Faculty of Medicine
ZF - Faculty of Health Sciences
Publication status:Published
Publication version:Version of Record
Submitted for review:10.03.2021
Article acceptance date:09.04.2021
Publication date:20.05.2021
Year:2021
Number of pages:12 str
Numbering:Vol. 8, art. 679073
PID:20.500.12556/RUL-132092 This link opens in a new window
UDC:636.09:616
ISSN on article:2297-1769
DOI:10.3389/fvets.2021.679073 This link opens in a new window
COBISS.SI-ID:63974403 This link opens in a new window
Publication date in RUL:12.10.2021
Views:598
Downloads:134
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Frontiers in veterinary science
Shortened title:Front. vet. sci.
Publisher:Frontiers Media
ISSN:2297-1769
COBISS.SI-ID:3969402 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:20.05.2021

Projects

Funder:ARRS - Slovenian Research Agency
Project number:P3-0003
Name:Razvoj in ovrednotenje novih terapij za zdravljenje malignih tumorjev

Funder:ARRS - Slovenian Research Agency
Project number:P4-0053
Name:Endokrini, imunski in encimski odzivi pri zdravih in bolnih živalih

Funder:ARRS - Slovenian Research Agency
Project number:J3-6796
Name:Translacijska onkologija: razvoj in validacija imunsko genske terapije z interleukinom-12 v kombinaciji s kirurgijo pri oralnih in kožnih tumorjih psov

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back